Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with or without vibostolimab in BCG-unresponsive high-risk non-muscle invasive bladder cancer
NL-OMON60483Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab and vibostolimab in non-muscle-invasive bladder cancer (NMIBC) (2 cohorts), sponsored by Merck & Co. Primary endpoints: Complete response rate of high-risk non-muscle invasive bladder cancer, 12-month disease-free survival rate of high-risk non-muscle invasive bladder cancer and 2 more. Started Aug 2016; status: completed.
02
Drugs
pembrolizumabvibostolimab
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NL-OMON60483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60483.